VRTX - Vertex Pharmaceuticals Incorporated
155.67 0.00 (0.00%)
After hours: 4:53PM EDT
| Previous Close | 158.69 |
| Open | 160.27 |
| Bid | 145.00 x 100 |
| Ask | 162.00 x 1000 |
| Day's Range | 154.69 - 160.49 |
| 52 Week Range | 113.66 - 178.15 |
| Volume | 1,223,744 |
| Avg. Volume | 1,737,453 |
| Market Cap | 39.677B |
| Beta | 1.94 |
| PE Ratio (TTM) | 149.83 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire•7 days ago
Vertex to Announce First Quarter 2018 Financial Results on April 26
Vertex Pharmaceuticals Incorporated will report its first quarter 2018 financial results on Thursday, April 26, 2018 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m.
- Business Wire•26 days ago
Vertex Appoints Kimberly A. White as Senior Vice President and Chief Communications Officer
Vertex Pharmaceuticals Incorporated today announced that Kimberly A. White has been appointed Senior Vice President and Chief Communications Officer. Ms. White will begin her role with Vertex on May 21, 2018, and will report to Michael J.
- Business Wire•last month
Vertex to Present at the Cowen Healthcare Conference on March 13
Vertex Pharmaceuticals Incorporated today announced that management will present at the Cowen Healthcare Conference on Tuesday, March 13, 2018 at 12:00 p.m. ET.
- GlobeNewswire•2 months ago
Consolidated Research: 2018 Summary Expectations for Envision Healthcare, Taylor Morrison Home, Vertex Pharmaceuticals, ReShape Lifesciences Inc., American Axle & Manufacturing, and Lattice Semiconductor — Fundamental Analysis, Key Performance Indications
NEW YORK, March 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- Business Wire•2 months ago
Vertex Initiates Phase 3 Study of VX-659, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation
Vertex Pharmaceuticals Incorporated today announced that it is initiating a Phase 3 study of VX-659, tezacaftor and ivacaftor as an investigational triple combination regimen for people with cystic fibrosis who have two copies of the F508del mutation, the most common genetic form of the disease.
- Business Wire•2 months ago
Vertex Appoints Reshma Kewalramani, M.D., as Chief Medical Officer
Vertex Pharmaceuticals Incorporated today announced that Reshma Kewalramani, M.D., has been appointed Chief Medical Officer and Executive Vice President, Global Medicines Development and Medical Affairs, effective April 1, 2018.
- Business Wire•2 months ago
Vertex Initiates First Phase 3 Study of VX-659, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis
Vertex Pharmaceuticals Incorporated today announced that it is initiating the first Phase 3 study of VX-659, tezacaftor and ivacaftor as an investigational triple combination regimen for people with cystic fibrosis who have one F508del mutation and one minimal function mutation.
- Business Wire•2 months ago
Vertex Announces Treatment with the NaV1.8 Inhibitor VX-150 Showed Significant Relief of Acute Pain in Phase 2 Study
Vertex Pharmaceuticals Incorporated today announced positive results of a Phase 2 study of the NaV1.8 inhibitor VX-150 in patients with acute pain following bunionectomy surgery.
- Business Wire•2 months ago
FDA Approves SYMDEKOTM (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Certain Mutations in the CFTR Gene
Vertex Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration approved SYMDEKO™ for treating the underlying cause of cystic fibrosis in people ages 12 and older who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator gene or who have at least one mutation that is responsive to tezacaftor/ivacaftor.
- ACCESSWIRE•3 months ago
Blog Exposure - BeiGene Commenced Dosing in Global Phase-3 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with ESCC
Stock Monitor: Vertex Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 02, 2018 / Active-Investors.com has just released a free research report on BeiGene, Ltd (NASDAQ: BGNE ). If you ...
- Business Wire•3 months ago
Vertex Selects Two Next-Generation Correctors, VX-659 and VX-445, to Advance into Phase 3 Development as Part of Two Different Triple Combination Regimens for People with Cystic Fibrosis
Vertex Pharmaceuticals Incorporated today announced the selection of two next-generation correctors, VX-659 and VX-445, to advance into Phase 3 development as part of two different triple combination regimens for people with cystic fibrosis .
- Business Wire•3 months ago
Vertex Reports Full-Year and Fourth-Quarter 2017 Financial Results
Vertex Pharmaceuticals Incorporated today reported consolidated financial results for the full year and fourth quarter ended December 31, 2017.
- Business Wire•3 months ago
Vertex Selects Two Next-Generation Correctors, VX-659 and VX-445, to Advance into Phase 3 Development as Part of Two Different Triple Combination Regimens for People with Cystic Fibrosis
Vertex Pharmaceuticals Incorporated today announced the selection of two next-generation correctors, VX-659 and VX-445, to advance into Phase 3 development as part of two different triple combination regimens for people with cystic fibrosis .
- ACCESSWIRE•3 months ago
Vertex Pharmaceuticals Incorporated to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / January 31, 2018 / Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) will be discussing their earnings results in their Q4 Earnings Call to be held on January 31, 2018 at ...
- Business Wire•3 months ago
Vertex Receives EU Approval for ORKAMBI® (lumacaftor/ivacaftor) in Children with Cystic Fibrosis Ages 6-11 with Two Copies of the F508del Mutation
Vertex Pharmaceuticals Incorporated today announced that the European Commission has granted extension of the Marketing Authorization for ORKAMBI® , the first medicine to treat the underlying cause of cystic fibrosis in people with two copies of the F508del mutation, to include children ages 6 through 11.
- Business Wire•4 months ago
Vertex Announces Upcoming Presentation at the J.P. Morgan Healthcare Conference and Date of Fourth-Quarter and Full-Year 2017 Financial Results
Vertex Pharmaceuticals Incorporated today announced that management will present at the J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 12:30 p.m. ET (9:30 a.m.
- ACCESSWIRE•4 months ago
Today’s Research Reports on Stocks to Watch: Teva Pharmaceutical and Vertex Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / December 14, 2017 / Teva shares sank almost 5% yesterday after traders showed concern over calls for protest in Israel over the company planning on cutting thousands of jobs ...
- Business Wire•4 months ago
Vertex and CRISPR Therapeutics to Co-Develop and Co-Commercialize CTX001 as CRISPR/Cas9 Gene Edited Treatment for Sickle Cell Disease and β-Thalassemia
Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics AG today announced that the companies will co-develop and co-commercialize CTX001, an investigational gene editing treatment, as part of the companies’ previously announced collaboration aimed at the discovery and development of new gene editing treatments that use the CRISPR/Cas9 technology.
- Business Wire•5 months ago
Vertex Announces Positive Results from Open-Label Phase 3 Study of KALYDECO® (ivacaftor) in Children with Cystic Fibrosis Ages 1 to 2 Years
Vertex Pharmaceuticals Incorporated today announced positive results from an open-label Phase 3 study of KALYDECO® in children with cystic fibrosis ages 1 to 2 years who have one of 10 mutations in the cystic fibrosis transmembrane conductance regulator gene.
- ACCESSWIRE•5 months ago
Earnings Review and Free Research Report: Vertex’s Revenue Soared 40%; Adjusted EPS Rocketed 212%
Research Desk Line-up: Esperion Therapeutics Post Earnings Coverage LONDON, UK / ACCESSWIRE / November 13, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on Vertex Pharmaceuticals ...
- Business Wire•5 months ago
Vertex Receives CHMP Positive Opinion for ORKAMBI® (lumacaftor/ivacaftor) for the Treatment of Children with Cystic Fibrosis Ages 6-11 with Two Copies of the F508del Mutation in the European Union
Vertex Pharmaceuticals Incorporated today announced that the European Union Committee for Medicinal Products for Human Use issued a positive opinion recommending extension of the Marketing Authorization for ORKAMBI® to children with cystic fibrosis ages 6 through 11 who have two copies of the F508del mutation.
- Business Wire•6 months ago
Vertex Announces Presentations of Data at North American Cystic Fibrosis Conference that Demonstrate Important Progress Toward Goal of Helping All People with CF
Vertex Pharmaceuticals Incorporated today announced presentations of data at the Annual North American Cystic Fibrosis Conference , November 2 to 4, 2017, in Indianapolis, from across the company’s portfolio of cystic fibrosis medicines and medicines in development that demonstrate important progress toward the company’s goal of helping all people with CF.
- Business Wire•6 months ago
Phase 3 Studies of the Tezacaftor/Ivacaftor Combination Treatment in People with Cystic Fibrosis Ages 12 and Older Published in the New England Journal of Medicine
Vertex Pharmaceuticals Incorporated announced today that the New England Journal of Medicine published two articles with results from two Phase 3 studies of the tezacaftor/ivacaftor combination treatment, a medicine in development that is designed to treat the underlying cause of cystic fibrosis in people ages 12 and older who have certain mutations in the cystic fibrosis transmembrane conductance ...
- Business Wire•6 months ago
Vertex to Present at the Credit Suisse Healthcare Conference on November 7
Vertex Pharmaceuticals Incorporated today announced that management will present at the Credit Suisse Healthcare Conference on Tuesday, November 7, 2017 at 10:35 a.m.